Michael Hearne - Nov 30, 2021 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO (LJPC)

Signature
/s/ Michael Hearne
Stock symbol
LJPC
Transactions as of
Nov 30, 2021
Transactions value $
$617
Form type
4
Date filed
12/2/2021, 04:05 PM
Previous filing
Nov 17, 2021
Next filing
Dec 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LJPC Common Stock Award $617 +186 +3.14% $3.32 6.11K Nov 30, 2021 Direct F1
holding LJPC Common Stock 10M Nov 30, 2021 By LP F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LJPC Employee Stock Option (Right to Buy) Award $0 +186 $0.00 186 Nov 30, 2021 Common Stock 186 $3.90 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired on 11/30/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.
F3 The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.